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ABSTRACT
Objectives: To explore factors influencing the
likelihood of antenatal vaccine acceptance of both
routine UK antenatal vaccines (influenza and pertussis)
and a hypothetical group B Streptococcus (GBS)
vaccine in order to improve understanding of how to
optimise antenatal immunisation acceptance, both in
routine use and clinical trials.
Setting: An online survey distributed to women of
childbearing age in the UK.
Participants: 1013 women aged 18–44 years in
England, Scotland and Wales.
Methods: Data from an online survey conducted to
gauge the attitudes of 1013 women of childbearing age
in England, Scotland and Wales to antenatal
vaccination against GBS were further analysed to
determine the influence of socioeconomic status, parity
and age on attitudes to GBS immunisation, using
attitudes to influenza and pertussis vaccines as
reference immunisations. Factors influencing likelihood
of participation in a hypothetical GBS vaccine trial were
also assessed.
Results: Women with children were more likely to
know about each of the 3 conditions surveyed (GBS:
45% vs 26%, pertussis: 79% vs 63%, influenza: 66%
vs 54%), to accept vaccination (GBS: 77% vs 65%,
pertussis: 79% vs 70%, influenza: 78% vs 68%) and
to consider taking part in vaccine trials (37% vs 27%
for a hypothetical GBS vaccine tested in 500 pregnant
women). For GBS, giving information about the
condition significantly increased the number of
respondents who reported that they would be likely to
receive the vaccine. Health professionals were the most
important reported source of information.
Conclusions: Increasing awareness about GBS, along
with other key strategies, would be required to optimise
the uptake of a routine vaccine, with a specific focus on
informing women without previous children. More
research specifically focusing on acceptability in
pregnant women is required and, given the value
attached to input from healthcare professionals, this
group should be included in future studies.
INTRODUCTION
Group B Streptococcus (GBS) is the most
common cause of sepsis and meningitis in
infants up to the age of 3 months with a sig-
niﬁcant morbidity and mortality.1 2 Current
prevention strategies (using intrapartum anti-
biotics) are aimed only at early onset group
B strep infections (occurring in the ﬁrst
week of life) and there are a number of chal-
lenges in their application in developed and
developing countries.3 Antenatal vaccination
is therefore an attractive prospect, and the
clinical trial of a candidate group B strep
vaccine is currently in phase II development.
Despite the promise of antenatal immun-
isation against group B strep, it is important
to be mindful that uptake rates for existing
antenatal vaccines are relatively low. In
England, antenatal inﬂuenza immunisation
Strengths and limitations of this study
▪ This is a large-scale study reporting the
responses of over a thousand women of child-
bearing age in the UK.
▪ A wide range of clinically important questions
were included regarding both current antenatal
vaccines and potential clinical trials which will be
of relevance to practitioners and researchers in
the UK and worldwide.
▪ A relatively small proportion of women (2%)
were actually pregnant at the time of the study
and data on the women’s ethnicity were not
collected.
▪ Though an online survey enables a large number
of participants to be included, it is limiting in
terms of the depth of information that can be
gathered. However, it can provide a useful pre-
liminary study to a more in-depth investigation
using qualitative methods.
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uptake was 44.1% in 2014/2015,4 despite clear beneﬁts
for the mother and child.5 Similarly, although antenatal
immunisation against neonatal pertussis has an effective-
ness of 91%6 and has been shown to be safe,7 uptake
rates in the UK are currently at 56.4%, a contributing
factor to the continuing tragedy of infant deaths from
this illness.8 It is therefore evident that simply the avail-
ability of a safe and effective antenatal vaccine does not
guarantee that it will be accepted by pregnant women,
and it is important to consider the relevance of this for
antenatal group B strep immunisation.
This paper presents further analysis of a previously
published online survey,9 in which we reported that 72%
of British women of childbearing age described them-
selves as ‘likely’ to receive a (hypothetical) antenatal
vaccine against group B strep, a ﬁgure that increased to
82% when further information about invasive group B
strep disease was provided. Presented here is a detailed
analysis of the relative differences in attitudes across sub-
groups of age, disease knowledge and parental status to
determine factors associated with increased likelihood of
vaccine acceptance or refusal.
METHODS
An online survey assessed awareness, perceptions of ser-
iousness and acceptability of antenatal vaccines for three
conditions: ‘whooping cough (also called pertussis) in
newborn babies’, ‘inﬂuenza in women while pregnant’
and ‘GBS (group B strep) infection in newborn babies’.
Preferred sources of advice about antenatal vaccination
were also investigated. The full survey questions and
response categories are included in table 1. For the
question ‘How serious do you think the following condi-
tions are?’, a non-infectious condition, ‘Heavy bleeding
in pregnancy’ was used as a comparison as it was
assumed that the majority of women would consider this
a serious condition. A ﬁve-level Likert scale was used for
all questions with the exception of one free-text answer.
A link to the survey was emailed to a nationally repre-
sentative sample of 1221 women aged between 18 and
44 years in England, Scotland and Wales by a market
research company (ComRes, London, 13–17 September
2013). These women had previously agreed to receive
emails from ComRes with surveys on a range of topics
including health, politics and social issues. Participation
was voluntary and no personal identifying information
was collected. Owing to the nature of this survey, formal
ethical approval was not required.
Demographic details were also collected including
age, social class, region and whether or not the respond-
ent had any children or was planning to have more chil-
dren. No personal identifying information was collected.
Respondents were assigned a social class based on their
reported occupation according to the Market Research
Society guidelines.10 Social classes were deﬁned accord-
ing to the National Readership Survey classiﬁcations
(available from http://www.nrs.co.uk/nrs-print/lifestyle-
and-classiﬁcation-data/social-grade/) and ranged from
A to E, with A deﬁned as being the highest social class
and E the lowest. Weighting adjustments were applied to
ensure a nationally representative sample.
Statistical comparisons between groups were carried
out using χ2 tests, Fisher’s exact test or χ2 test for trend
using a software package (Graphpad prism V.6). For
clarity of presentation in the tables, answers to questions
2, 3, 4, 5, 7 and 8 were collapsed into ‘don’t know what
it is’, ‘know what it is’ and ‘have been directly affected’
for question 2; ‘serious’, ‘not serious’ and ‘don’t know’
for question 3; ‘likely’, ‘unlikely’ and ‘don’t know’ for
questions 4, 5 and 7; and ‘important’, ‘not important’
and ‘don’t know’ for question 8. Where signiﬁcant dif-
ferences were found between subcategories, for
example, ‘never heard of it’ and ‘heard of it but don’t
know what it is’ in question 2, these are indicated in the
text. The full breakdown of answers is publicly available
at http://www.comres.co.uk/poll/1028/gbs-vaccination-
survey.htm. Free-text responses to the question, ‘Why
would you be willing/unwilling to have a group B strep
vaccine in pregnancy?’ were analysed for recurrent
themes and grouped accordingly, for example, ‘to
protect my baby’s health’ or ‘do not like/believe in
vaccines’.
Quality control measures used to ensure that respon-
dents were paying due attention included a series of
logic checks such as matching date of birth with age
band and asking participants to identify shapes and
colours.
RESULTS
Of the 1221 women surveyed, 1013 returned usable
answers (83%). Of those who did not, 138 (11%) did
not complete the survey, 13 (1%) did not meet the
inclusion criteria (eg, incorrect age or gender), 12
(1%) completed the survey after the recruitment target
had been reached and 43 (4%) were discounted as they
failed quality control. The proportions of respondents
with and without children are shown in ﬁgure 1 and
the numbers in each age category in table 2.
Twenty-ﬁve per cent of the respondents were in social
classes A and B (higher and intermediate managerial/
professional), 29% in C1 (supervisory, clerical and
junior managerial/professional), 17% in C2 (skilled
manual) and 29% in DE (semiskilled, unskilled and
unemployed). These social class percentages are similar
to that of the 2011 household census for England and
Wales.11
Factors influencing awareness and attitudes to pertussis,
influenza and group B strep
Though similar proportions of respondents had been
directly affected by each of the conditions (pertussis 5%,
inﬂuenza 3% and group B strep 4%), less was known
about group B strep compared with pertussis or inﬂu-
enza (‘never heard of’—pertussis: 6%; inﬂuenza: 14%;
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Table 1 Survey questions and possible responses
Question Possible responses
1. Which one of the following statements best describes your
current situation?
a. I have one or more children and don’t plan to have
any more.
b. I have one or more children and plan to have more.
c. I am/my partner is currently pregnant.
d. I don’t have any children now, but hope to have one
or more children in the future.
e. I don’t have any children and don’t expect to in the
future.
2. How familiar are you with the following conditions?
▸ Whooping cough (also called pertussis) in newborn babies
▸ Influenza in women while pregnant
▸ Group B streptococcus (group B strep) infection in newborn
babies
a. I have never heard of it
b. I have heard of it, but I don’t know what it is
c. I have heard of it, and I know what it is
d. I know what it is, and I have been affected by it
directly
3. How serious do you think the following conditions are?
▸ Heavy bleeding in pregnancy (for mother or newborn child)
▸ Whooping cough (also called pertussis) in newborn babies
▸ Influenza in women while pregnant
▸ Group B streptococcus (group B strep) infection in newborn
babies
a. Very serious
b. Fairly serious
c. Not very serious
d. Not serious at all
e. Don’t know
4. How likely or unlikely would you be willing to receive the
following vaccines during pregnancy?
▸ Vaccine against whooping cough (pertussis)
▸ Vaccine against influenza
▸ Vaccine against group B strep infection
a. Very likely
b. Fairly likely
c. Fairly unlikely
d. Very unlikely
e. Don’t know
Information provided about group B strep
Group B strep is the UK’’s most common cause of meningitis and life-threatening infection in newborn babies. About 20% of
UK women carry group B strep bacteria without having any symptoms. Babies can be exposed at birth and afterwards from
the mother and from other sources. Most will not develop infection but about 600–700 babies a year in the UK do. Currently,
antibiotics can be given during labour if the mother is considered to be at high risk of having a baby with group B strep
infection, but this does not prevent all infections.
A vaccine for pregnant women to protect their babies against group B strep is being developed. This vaccine has so far been
given to many adults and to a small number of pregnant women in research studies. These studies have found no evidence
of harm to the women or their unborn babies and the results suggest that the vaccine could prevent most group B strep
infections in babies.
5. After reading the description above, how likely or unlikely would
you be willing to receive a vaccine against group B strep during
pregnancy?
a. Very likely
b. Fairly likely
c. Fairly unlikely
d. Very unlikely
e. Don’t know
6. Could you explain why you would be likely/unlikely to be willing
to receive a vaccine against group B strep during pregnancy?
a. __________________
b. I prefer not to say
7. Specifically, how likely or unlikely would you be willing to
receive a group B strep vaccine during pregnancy in each of the
following situations?
▸ As part of a research study looking at how well this vaccine
protects infants against group B strep, before the vaccine is
licensed (approved for routine use in pregnancy) if the vaccine
had been given to 500 pregnant women without significant
safety concerns
▸ As part of a research study looking at how well this vaccine
protects infants against group B strep, before the vaccine is
licensed (approved for routine use in pregnancy) if the vaccine
had been given to 5000 pregnant women without any
significant safety concerns
▸ If the vaccine was licensed (approved for use), but not
specifically recommended for routine use by the NHS
▸ If the vaccine was licensed and recommended for routine use
by the NHS
a. Very likely
b. Fairly likely
c. Fairly unlikely
d. Very unlikely
e. Don’t know
Continued
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group B strep: 29%, p<0.0001). Those with children
were signiﬁcantly more likely than those without to
know about each condition (see table 2), as were older
women compared with younger women. However, as
expected, older women were also more likely to have
children (percentage with children: 18–24y ears: 26%,
25–34 years: 54%, 35–44 years: 74%, p<0.0001). There
were no statistically signiﬁcant differences in awareness
by social class.
Older women, those with children and those with
knowledge of the relevant condition were more likely to
consider pertussis and group B strep to be serious; for
inﬂuenza, the differences were not signiﬁcant (table 2).
Generally, a higher proportion of respondents rated per-
tussis as more serious compared with both inﬂuenza and
group B strep (pertussis 88% vs inﬂuenza 82%,
p=0.0002; pertussis 88% vs group B strep 79%,
p<0.0001). However, of those who reported that they
knew what the speciﬁc condition was or had experi-
enced it themselves; 92% rated both pertussis and group
B strep as either very serious or fairly serious. A higher
proportion of these respondents who knew about group
B strep also rated it as very serious, rather than fairly
serious compared with pertussis (67% vs 59%,
p=0.0037).
Factors influencing attitudes to immunisation and clinical
trials
The likelihood of accepting antenatal vaccination for all
three conditions was not affected by age (table 2) or
social class (pertussis: AB 77%, C1 73%, C2 79%, DE
72%; inﬂuenza: AB 74%, C1 69%, C2 77%, DE 69%;
and group B strep: AB 75%, C1 68%, C2 76%, DE 70%;
all comparisons non-signiﬁcant). Those who already had
children or knew about the condition were signiﬁcantly
more likely to be willing to receive a vaccine in preg-
nancy (table 2). Giving information about group B strep
signiﬁcantly increased the likelihood of accepting an
antenatal vaccine in all groups (table 3).
Eight-hundred and ninety-eight respondents commen-
ted in the free-text section about the reasons why they
would or would not accept antenatal group B strep vac-
cination. Of those who reported that they would be
likely to accept the vaccine, the most frequently
expressed views were a desire ‘to protect my baby/baby’s
health’ (27%) and the vaccine being a preventive
measure (15%). Forty-three respondents stated that they
would need more information before making a ﬁnal
decision and 12 questioned the risks/safety of the
vaccine. Of those who would be unwilling to have an
antenatal group B strep vaccine, 24% (16/63) stated
that they did not like/believe in vaccines with the next
most common issue being that they required more infor-
mation (19%, 13/63) or felt there was a lack of safety
evidence (17%, 11/63).
A speciﬁc recommendation for use by the National
Health Service (NHS), as opposed to the vaccine simply
being licensed and available, signiﬁcantly increased the
likelihood of respondents accepting the group B strep
Table 1 Continued
Question Possible responses
8. Please indicate how important, or otherwise, you would
consider the advice of each of the following in making a decision
as to whether or not you would be comfortable to receive (or for
your partner to receive) a group B strep vaccine during
pregnancy.
▸ Partner
▸ A midwife
▸ An obstetrician
▸ Your GP
▸ Written handouts provided by the NHS
▸ Information on the internet, for example, parent forums
▸ The media
▸ Friends and family
▸ Other
▸ Very important
▸ Fairly important
▸ Not very important
▸ Not at all important
▸ Don’t know
GP, general practitioner; NHS, National Health Service.
Figure 1 Distribution of respondents by parental status.
N=1013 women aged 18–44 years.
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Table 2 Survey responses by age, parental status and previous knowledge of the condition
18–24 years
(% of n=239)
25–34 years
(% of n=359)
35–44 years
(% of n=415) p Value
Children
(% of n=570)
No children
(% of n=443) p Value
Know what
it is (% of n†)
Don’t know
what it is
(% of n†) p Value
How serious would you consider the following conditions?
Heavy bleeding in pregnancy
Serious 91 94 96 0.03 96 91 0.0011
Don’t know 5 5 4 2 7
Not serious 4 1 0 0.002 1 2 NS
Pertussis
Serious 82 86 94 <0.0001 92 83 <0.0001 92 79 <0.0001
Don’t know 11 9 5 5 12 4 18
Not serious 6 4 1 0.003 3 5 NS 4 3 NS
Influenza
Serious 81 80 85 NS 85 80 NS 88 74 <0.0001
Don’t know 14 12 8 8 16 5 21
Not serious 5 8 6 NS 8 4 0.0268 7 5 NS
Group B strep
Serious 72 75 86 <0.0001 84 72 <0.0001 92 71 <0.0001
Don’t know 21 20 12 12 24 4 26
Not serious 7 4 1 0.0014 3 4 NS 5 3 NS
How likely would you be to have a vaccine for the following conditions in pregnancy?
Pertussis
Likely 75 76 72 NS 79 70 0.0018 77 67 0.0013
Don’t know 18 15 19 12 23 44 25
Unlikely 6 9 9 NS 9 7 NS 8 8 NS
Influenza
Likely 73 72 70 NS 75 68 0.0211 76 65 0.0002
Don’t know 18 16 18 12 23 11 26
Unlikely 9 12 12 NS 13 9 0.0437 12 9 NS
Group B strep (pre information)
Likely 72 72 72 NS 77 65 <0.0001 79 67 <0.0001
Don’t know 22 19 20 14 28 11 25
Unlikely 6 10 8 NS 9 7 NS 10 8 NS
Group B strep (post information)
Likely 80 81 85 NS 86 77 <0.0001 86 80 0.0217
Don’t know 13 11 10 7 16 7 14
Unlikely 6 8 5 NS 6 6 NS 7 6 NS
Answers were mutually exclusive and p values indicate differences between groups for that answer versus all other answers.
NS, non-significant, that is, p>0.05. Percentages are rounded to the nearest whole number.
†Know what it is: pertussis n=727, flu n=609, group B strep n=374. Don’t know what it is: n=286, flu n=404, group B strep n=639.
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vaccine (79% vs 52%, p<0.0001), proportions that
remained higher in those with previous knowledge
about group B strep (table 4).
A smaller proportion of women were likely to receive
an antenatal group B strep vaccine as part of a research
study than if licensed (42% (if previously given to 5000
women) or 32% (if previously given to 500 pregnant
women) vs 52% (if licensed but not routinely recom-
mended)). In early stage development (ie, vaccine admi-
nistered to fewer than 500 pregnant women), previous
knowledge of group B strep increased the likelihood of
respondents being willing to take part in a research
study; however, it made no difference to this decision if
the vaccine had been given to 5000 pregnant women
(table 4). Age and social class made no difference to the
proportion of women willing to take part in group B
strep vaccine research, but a higher percentage of those
who already had children reported that they would be
likely to be willing to receive a group B strep vaccine as
part of a clinical trial (table 4).
Sources of advice
The importance to women of advice from various
sources in making decisions about antenatal vaccination
is shown in ﬁgure 2. General practitioners (GPs) were
the source of advice rated as important by the highest
proportion of respondents (87%) closely followed by
midwives (84%). Twenty per cent more women felt that
written NHS handouts were more important compared
with internet sources such as parent forums (78% vs
58%) and half indicated that the media was not an
important source of advice for them. Generally, older
respondents (35–44 years) were more likely to rate
advice from maternity health professionals as important
than the youngest age group (midwife: 18–24 years
(79%), 35–44 years (87%), p<0.01; obstetrician: 18–
24 years (69%), 35–44 years (86%), p<0.0001), women
aged 25–34 years also followed this trend (group differ-
ences were statistically signiﬁcant for obstetricians but
not midwives). However, younger women were more
likely to rate advice from friends and family as important
(18–24 years (72%), 25–34 years (64%), 35–44 years
(62%), p<0.005). There were no signiﬁcant age group
differences in ratings for partners, the internet or the
media. Those with children rated each of the sources as
more important than those without children, although
those without children were more likely to answer ‘don’t
know’.
DISCUSSION
These ﬁndings emphasise the critical importance of
information about group B strep to optimise uptake of a
potential antenatal vaccine, and that this may need to be
speciﬁcally targeted at women in their ﬁrst pregnancy.
Even a brief explanation about group B strep increased
the likelihood of vaccine acceptance by 7–13% and a
speciﬁc national recommendation for its use signiﬁ-
cantly increased the potential uptake rate; however, it is
important to combine this information with other strat-
egies to promote uptake. Women of childbearing age
rate the importance of advice from healthcare profes-
sionals, particularly their GP, very highly.
This survey forms part of a larger project funded by
Meningitis Now entitled ‘Preparing the UK for an effect-
ive Group B streptococcus vaccine’, and was designed to
provide preliminary information on the views of the UK
population about GBS and a possible antenatal vaccine.
The potential for vaccination against group B strep is
particularly important as a trivalent glycoconjugate
vaccine has recently been trialled in over 300 pregnant
women with no vaccine-related safety concerns and
large-scale clinical trials are likely to begin in the near
future.12 13 Universal antenatal vaccination against
group B strep could have several advantages over intra-
partum antibiotics. It would most likely protect against
both early-onset and late-onset disease, while intrapar-
tum antibiotics are only able to prevent early-onset infec-
tion. Concerns about antibody resistance and the
practical issue of administering intravenous antibiotics at
least 2 h before birth would no longer be relevant. This
is particularly important as in one UK study, 81% of
mothers whose babies went on to develop group B strep
disease had not received adequate intrapartum antibio-
tics, despite having risk factors.14 Primary prevention
through vaccination could potentially avoid these situa-
tions; however, more information is needed on the
immunogenicity and safety of the vaccine and, most
importantly, whether or not it would be acceptable to
pregnant women.
While it is encouraging that over 70% of respondents
reported that they would be likely to have antenatal
Table 3 Effect of providing information about group B strep (see table 1) on likelihood of being willing to receive a group B
strep vaccine in pregnancy
Group Preinformation (%) Postinformation (%) p Value
18–24 years (n=239) 185 (72) 208 (80) 0.0236
25–34 years (n=359) 255 (72) 289 (81) 0.0038
35–44 years (n=415) 286 (72) 337 (85) <0.0001
Children (n=557) 428 (77) 481 (86) <0.0001
No children (n=456) 297 (65) 352 (77) <0.0001
Prior knowledge (n=374) 297 (79) 321 (86) 0.0262
No prior knowledge (n=639) 429 (67) 512 (80) <0.0001
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vaccinations against the three conditions surveyed, in
reality vaccine uptake is much lower. The peak uptake
for antenatal pertussis vaccine in England was 61.5% in
November 2013 and has since fallen,8 15 despite guide-
lines that it should be routinely offered to all pregnant
women in the UK between 28 and 38 weeks’ gestation.16
The percentage of pregnant women receiving the inﬂu-
enza vaccine, which is recommended for all pregnant
women in the UK regardless of gestation during the
inﬂuenza season, is only around 44.1%.4 The reasons for
these low rates are varied and much of the published
work has focused on inﬂuenza vaccination in pregnancy.
A number of strategies to promote antenatal vaccine
uptake have been tried, again particularly focusing on
immunisation against inﬂuenza. In Stockport, Greater
Manchester, UK, antenatal inﬂuenza vaccination uptake
increased by almost 15% over 1 year through concen-
trated efforts using local media/social media, establish-
ing links between midwifery and GP services, improving
IT services, education of staff and good leadership.17
Similarly, an Australian campaign based on raising
health professionals’ awareness of antenatal inﬂuenza
vaccination through lectures and meetings, new patient
information booklets and visual reminders on patient
notes increased inﬂuenza vaccine uptake from 30% to
40%.18 Our results also indicate that knowledge about
the condition being prevented and support from health-
care professionals are key, and even brief interventions,
such as the short paragraph about group B strep used in
this survey, can signiﬁcantly impact on the likelihood of
vaccine uptake.
There is less information regarding attitudes towards
antenatal group B strep vaccination, but this is a growing
area of research. A recently published survey of 231
pregnant or recently delivered women in the USA
showed remarkably similar results to this survey in that
79% of respondents indicated that they would be likely
to have a group B strep vaccine in pregnancy.19
Although 90% indicated that they were concerned
about the safety of new antenatal vaccines, 95% of those
surveyed responded that they generally followed their
healthcare professional’s recommendations. A Canadian
qualitative study also found that a healthcare profes-
sional’s recommendation would be a major factor in
whether or not they would accept the vaccine, and con-
cerns about safety were also raised.20 Our ﬁndings
suggest that while there are certain groups who may be
more receptive to antenatal vaccination, there are
others, such as women in their ﬁrst pregnancy, who may
require additional input to encourage vaccine uptake.
These women may be more accepting if the antenatal
vaccines are nationally recommended and may require
extra time and provision of information to optimise dis-
cussion of vaccination options, particularly those focus-
ing on the nature and seriousness of the conditions that
are being vaccinated against.
There are a number of limitations to these ﬁndings
that must be acknowledged. Respondents to the survey
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had volunteered to receive such questionnaires on mul-
tiple occasions and on various topics and therefore may
be more open to research in general. There were few
pregnant women within the sample and it is the views of
these women, for whom the questions are not merely
theoretical, which are key. However, the sample was rela-
tively large and representative in terms of age, geog-
raphy and social class, and therefore provides a useful
framework on which to build future work. Of note, data
on the women’s ethnicity were not collected, which may
be an important factor. The nature of an online survey
also means that in-depth exploration of the decision-
making process is not possible and more detail is
needed on women’s information requirements and how
this should be delivered. Other details are lacking, such
as how women self-deﬁned being directly affected by the
condition and why such a high proportion of women
who did not know what the conditions were still rated
them as serious. The rates reported here are higher
than the invasive disease rates and some of those
without children also considered themselves to have
been directly affected by each of the conditions suggest-
ing response bias. This may have been the result of con-
fusion over what was being asked in this question or this
group may contain relatives/friends of affected parents
or women who have had a positive group B strep swab
in pregnancy, rather than an affected child. However,
this is consistent across all the conditions surveyed and it
seems that this experience is sufﬁcient to sway attitudes
towards group B strep.
It is with these limitations in mind that further
research on the acceptability of group B strep immunisa-
tion in pregnant women in the UK is being conducted
using focus groups, interviews and questionnaires to spe-
ciﬁcally obtain the views of pregnant women and mater-
nity healthcare professionals. If these ﬁndings support
the data presented here, then, depending on the devel-
opment of an effective and safe vaccine, immunisation
of pregnant women against group B strep could be the
next major breakthrough in the prevention of neonatal
sepsis and meningitis.
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